<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1148">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05146206</url>
  </required_header>
  <id_info>
    <org_study_id>20210902_2</org_study_id>
    <nct_id>NCT05146206</nct_id>
  </id_info>
  <brief_title>Patient Satisfaction and Sensory Attributes Allergic Rhinitis Nasal Spray</brief_title>
  <official_title>Patient Satisfaction and Sensory Attributes of Nasal Spray Treatments for Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Community and Patient Preference Research Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seqirus Limited</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Glenmark Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Community and Patient Preference Research Pty Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study seeks to understand patients' satisfaction and importance of treatment attributes&#xD;
      for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study seeks to understand patients' satisfaction and importance of treatment attributes&#xD;
      for Allergic Rhinitis nasal sprays from two brands (RYALTRIS® vs. DYMISTA®).&#xD;
&#xD;
      To directly compare patient satisfaction with 2 different Allergic Rhinitis nasal sprays, an&#xD;
      observational, cross-sectional study design with 2 independent samples was chosen.&#xD;
      Participants will complete an online survey involving a Best-Worst scaling (BWS) task to&#xD;
      determine satisfaction and importance index for sensory attributes.&#xD;
&#xD;
      The suggested treatment attributes are informed by a range of previous studies, including&#xD;
      those conducted by Meltzer et al 2005 and Price et al 2020, and methodology from CaPPRe's own&#xD;
      work in developing indices for importance and satisfaction of treatment attributes using BWS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 8, 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Best-Worst Scaling task index score</measure>
    <time_frame>Cross-sectional - through study completion, an average of 3 months</time_frame>
    <description>The primary study endpoint is the overall index score from the Best Worst Scaling exercise, to reflect satisfaction and importance of treatment attributes of the RYALTRIS® and DYMISTA® nasal spray.&#xD;
Index scores from the Best Worst Scaling exercise range from 0 to 100, with higher scores indicating higher satisfaction of treatment attributes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Domain scores from Best-Worst Scaling task</measure>
    <time_frame>Cross-sectional - through study completion, an average of 3 months</time_frame>
    <description>Secondary study endpoints are the Best Worst Scaling domain scores from the Best Worst Scaling exercise (i.e., relative ranking scores for each of the domains; satisfaction and importance).&#xD;
Best-Worst Scaling domain scores range from -1 to 1 and represent the relative ranking (ordering) of the domains. A negative score indicates the domain was chosen as worst more often than best. A positive score indicates the domain was chosen as best more often than worst. A zero score indicates the domain was chosen as best and worst an equal number of times OR was never chosen.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Patients on RYALTRIS</arm_group_label>
    <description>Patients who are currently using RYALTRIS nasal spray.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients on DYMISTA</arm_group_label>
    <description>Patients who are currently using DYMISTA nasal spray.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Observational</intervention_name>
    <description>In this observational study, participants initated on RYALTRIS/DYMISTA nasal spray will complete a cross-sectional online survey that includes a Best-Worst Scaling task to capture their satisfaction and importance of various treatment attributes.</description>
    <arm_group_label>Patients on DYMISTA</arm_group_label>
    <arm_group_label>Patients on RYALTRIS</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The primary population will be patients with moderate to severe SAR or PAR with or without&#xD;
        conjunctivitis in Australia who have been initiated on RYALTRIS® or DYMISTA® in that last&#xD;
        12 months.&#xD;
&#xD;
        The expected sample size is between 200 to 400 patients. 100-200 patients initiated on&#xD;
        RYALTRIS® and 100-200 patients initiated on DYMISTA® nasal spray in the last 12 months.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Allergic Rhinitis patients (moderate-to-severe Seasonal Allergic Rhinitis or Perennial&#xD;
        Allergic Rhinitis) with or without conjunctivitis who meet the following criteria will be&#xD;
        offered the opportunity to participate in the study:&#xD;
&#xD;
          -  Patients above 18 years old&#xD;
&#xD;
          -  Fluent in English&#xD;
&#xD;
          -  Patients initiated on RYALTRIS® or DYMISTA® nasal spray in the last 12 months and&#xD;
             currently using treatment&#xD;
&#xD;
          -  Willing and able to provide consent to participate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have reported a loss of taste and/or smell related to COVID-19 (or other medical&#xD;
             condition)&#xD;
&#xD;
          -  Are employed by a pharmaceutical company (to avoid conflict of interest)&#xD;
&#xD;
          -  Are employed by a vaccine company (to avoid conflict of interest)&#xD;
&#xD;
          -  Do not have access to the internet (to ensure validity of the data)&#xD;
&#xD;
          -  Are unable to read and understand English (to ensure validity of the data)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Fifer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Community and Patient Preference Research Pty Ltd</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Li Toh, B.PsycSc</last_name>
    <phone>+61 452551409</phone>
    <email>lili.toh@cappre.com.au</email>
  </overall_contact>
  <location>
    <facility>
      <name>Community and Patient Preference Research Pty Ltd</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Li Toh, B.PsycSc</last_name>
      <phone>+61452551409</phone>
      <email>lili.toh@cappre.com.au</email>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <reference>
    <citation>Australian Institute of Health and Welfare 2019. Allergic rhinitis ('hay fever'). Cat. no. PHE 257. Canberra: AIHW. Viewed 01 May 2020, https://www.aihw.gov.au/reports/chronic-respiratory-conditions/allergic-rhinitis-hay-fever/contents/allergic-rhinitis</citation>
  </reference>
  <reference>
    <citation>Meltzer EO, Bardelas J, Goldsobel A, Kaiser H. A preference evaluation study comparing the sensory attributes of mometasone furoate and fluticasone propionate nasal sprays by patients with allergic rhinitis. Treat Respir Med. 2005;4(4):289-96.</citation>
    <PMID>16086602</PMID>
  </reference>
  <reference>
    <citation>Meltzer EO, Garadi R, Laforce C, Chadwick SJ, Berger WE, Gross G, Edwards MR, Crenshaw K, Wall GM. Comparative study of sensory attributes of two antihistamine nasal sprays: olopatadine 0.6% and azelastine 0.1%. Allergy Asthma Proc. 2008 Nov-Dec;29(6):659-68. doi: 10.2500/aap.2008.29.3181. Epub 2008 Dec 6.</citation>
    <PMID>19144261</PMID>
  </reference>
  <reference>
    <citation>Meltzer EO, Hadley J, Blaiss M, Benninger M, Kimel M, Kleinman L, Dupclay L, Garcia J, Leahy M, Georges G. Development of questionnaires to measure patient preferences for intranasal corticosteroids in patients with allergic rhinitis. Otolaryngol Head Neck Surg. 2005 Feb;132(2):197-207.</citation>
    <PMID>15692526</PMID>
  </reference>
  <reference>
    <citation>Price D, Klimek L, Gálffy G, Emmeluth M, Koltun A, Kopietz F, Nguyen DT, van Weissenbruch R, Pohl W, Kuhl HC, Scadding G, Mullol J. Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma. Clin Mol Allergy. 2020 Aug 6;18:15. doi: 10.1186/s12948-020-00130-9. eCollection 2020.</citation>
    <PMID>32782442</PMID>
  </reference>
  <reference>
    <citation>Louviere, J., Flynn, T., Marley, A., 2015. References. In Best-Worst Scaling: Theory, Methods and Applications Cambridge University, Cambridge, pp. 316-331</citation>
  </reference>
  <reference>
    <citation>Mühlbacher AC, Kaczynski A, Zweifel P, Johnson FR. Experimental measurement of preferences in health and healthcare using best-worst scaling: an overview. Health Econ Rev. 2016 Dec;6(1):2. doi: 10.1186/s13561-015-0079-x. Epub 2016 Jan 8.</citation>
    <PMID>26743636</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 10, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 23, 2021</last_update_submitted>
  <last_update_submitted_qc>November 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patient preference</keyword>
  <keyword>Best-Worst Scaling</keyword>
  <keyword>Treatment attributes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

